Skip to main content

Table 1 Baseline patient characteristics

From: Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study

Characteristic

mFOLFIRINOX (n = 27)

Gemox (n = 22)

P value

Age

 Median, range

58 (41–73)

56.5 (36–75)

0.817

Sex

  

0.181

 Male

15 (55.6)

8 (36.4)

 

 Female

12 (44.4)

14 (63.6)

 

ECOG

  

0.407

 0

13 (48.1)

8 (36.4)

 

 1

14 (51.9)

14 (63.6)

 

Primary tumor sites

  

0.434

 Intrahepatic

16 (59.3)

9 (40.9)

 

 Hilar

9 (33.3)

11 (50.0)

 

 Distal

2 (7.4)

2 (9.1)

 

Disease status

  

0.276

 Locally advanced

6 (22.2)

8 (36.4)

 

 Metastatic

21 (77.8)

14 (63.6)

 

Metastatic site

 Liver

17 (63.0)

13 (59.1)

0.782

 Lung

5 (18.5)

2 (9.1)

–

 Bone

1 (3.7)

0 (0)

–

 Other

1 (3.7)

1 (4.5)

–

CA19–9

 Median, range

172.0 (6.5–18,940)

151.3 (1.7–26,666)

0.680

  1. ECOG Eastern Cooperative Oncology Group
  2. Data are presented as n (%) for categorical variables and as median (range) for continuous variables